about
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphomaA fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumorsPhase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study.Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesExploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavageCharacteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemiaGILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?Dormant tumor cells as a therapeutic target?Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells.Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.Tumor dormancy and immunoescape.B7-H3 protein expression in acute myeloid leukemia.Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia.Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes.GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation.Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs.Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia.MYD88 L265P mutation in Waldenstrom macroglobulinemia.The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity.Copy-number analysis identified new prognostic marker in acute myeloid leukemia.Outcome of older patients with acute myeloid leukemia in first relapse.Synthesis and biological evaluation of phenstatin metabolites.A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
P50
Q27851480-F16B7E6B-1B0A-4B62-B88C-EC77C30F983CQ28207718-5796DA91-D980-4546-9462-D8FB70175633Q28510246-8B145108-0AF7-4824-A9FE-B74253D82B05Q31364111-B2C9BBE3-7EC1-408A-A380-FEAC27D3648BQ32063856-8617048C-55BA-4330-BC05-29E19566C83FQ33518976-8EB509AE-BD7A-49DF-9886-2C5F5F203131Q33971155-FAA7B12D-C4E5-474E-8CE8-DC99B00E7134Q34046624-84FCAF7D-5181-4707-BC08-8DECCE7E9B81Q34128478-D9FFA03D-EA22-424F-88BC-93A362DF09A1Q34435295-E77C75E6-F2E0-47A1-B4BA-2D26A39BED13Q34516294-C176E2CE-FEF9-4584-B832-2FC7C220EF81Q34574352-EA7D6DEF-A6A2-4178-9B96-3347D77C6AF1Q34646570-D43D4598-1E41-4311-A561-505448260322Q34650186-70462B2C-E22F-46A0-BCA9-0975203069E3Q35679558-579CEFFB-33D3-422E-A905-460FED63A1CDQ35836896-3DFBD058-C7CA-44AD-AB0A-B2A0138EE607Q35853026-3174021D-8142-4531-ADCB-71AC62B8EF14Q36368265-EB7B0DA0-C157-4B9E-909B-91DB65ADBA4BQ36561772-43AF4EA3-C6DB-4574-8029-F89BFDF4097BQ36627526-38D2EB8A-26BA-40D4-8C21-3C7E5743CDE6Q36690273-DBCA7569-A4DA-4D44-B872-51F6EE1996EAQ37126959-DAB97A60-0287-4169-9435-83BE03CE39BDQ37134211-482E2634-D74A-48C9-9F2F-DB80B991FAECQ37158530-98D65724-540F-495D-8C34-E66EA8939026Q37286268-8736EEE4-A39D-47D9-9C1C-3082FE112E38Q37441516-89ACCC7D-C412-4B40-935C-E3F997FF479AQ37457568-401FF6FC-7837-4A2D-B17D-1C08030DEA82Q37641783-50212ED8-35B4-4E44-A272-533991A1EA29Q38343881-5EBDB9AD-57F4-4670-A98C-BE2B55E39DEEQ38650100-5AC8DA53-A8C0-40D8-8453-C9E859C0B485Q38688166-B2BF1C5B-AA69-4F80-8737-D764580C3C33Q38758165-EB4321BE-2982-4072-9522-7C3443042A8AQ38929358-7284C3AF-BBA0-4732-BC45-2A1ED059AF76Q39100783-23691C4D-8EDC-4314-96CB-DCDF41A7892BQ39175169-55764E12-4F47-4926-B259-9C0B22C83E76Q39203640-AD53C431-FF17-412F-85CC-B4964478FE57Q39337506-14309A89-CC1E-4BCF-83A7-43E8D568A093Q39405204-61D0A035-6124-46C2-857C-55751F6EE43EQ39473253-7D203A21-FA72-4CF5-8FEF-E8B576CDD4B9Q39769270-889F6005-45E0-4B79-8C81-9852E3A70DB0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruno Quesnel
@ast
Bruno Quesnel
@en
Bruno Quesnel
@es
Bruno Quesnel
@nl
type
label
Bruno Quesnel
@ast
Bruno Quesnel
@en
Bruno Quesnel
@es
Bruno Quesnel
@nl
prefLabel
Bruno Quesnel
@ast
Bruno Quesnel
@en
Bruno Quesnel
@es
Bruno Quesnel
@nl
P106
P21
P31
P496
0000-0002-6563-2709